LYVE1 and primary effusion lymphoma: A recent study pointed out that in human primary effusion lymphoma (PEL) tumor cells, when LYVE-1 and EMMPRIN/CD147 coexpressed with drug transporter protein, breast cancer resistance protein/ABCG2 (BCRP), EMMPRIN induced upregulation of BCRP, and LYVE-1 colocalized with BCRP on the cell surface, suggesting that LYVE-1 takes part in facilitating hyaluronan and EMMPRIN-mediated chemoresistance.